دورية أكاديمية
أعرض في EDS

Chronic treatment with baicalein alleviates behavioural disorders and improves cerebral blood flow via reverting metabolic abnormalities in a J20 transgenic mouse model of Alzheimer's disease.

التفاصيل البيبلوغرافية
العنوان: Chronic treatment with baicalein alleviates behavioural disorders and improves cerebral blood flow via reverting metabolic abnormalities in a J20 transgenic mouse model of Alzheimer's disease.
المؤلفون: Zhang L; Integrative Sciences and Engineering Programme, NUS Graduate School, National University of Singapore, Singapore, 117583, Singapore.; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, 117543, Singapore., Wong LR; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, 117543, Singapore., Wong P; Neuroscience Phenotyping Core, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117456, Singapore., Shen W; Department of Chemistry, Faculty of Science, National University of Singapore, Singapore, 117543, Singapore., Yang S; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, 117543, Singapore., Huang L; School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China., Lim YA; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117600, Singapore., Ho PC; Integrative Sciences and Engineering Programme, NUS Graduate School, National University of Singapore, Singapore, 117583, Singapore.; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, 117543, Singapore.; Monash University Malaysia, School of Pharmacy, Subang Jaya, 47500, Selangor, Malaysia.
المصدر: Brain, behavior, & immunity - health [Brain Behav Immun Health] 2023 Jan 31; Vol. 28, pp. 100599. Date of Electronic Publication: 2023 Jan 31 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101759062 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3546 (Electronic) Linking ISSN: 26663546 NLM ISO Abbreviation: Brain Behav Immun Health Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [New York] : Elsevier Inc., [2020]-
مستخلص: Baicalein (BE) has both antioxidant and anti-inflammatory effects. It has also been reported able to improve cerebral blood circulation in brain ischemic injury. However, its chronic efficacy and metabolomics in Alzheimer's disease (AD) remain unknown. In this study, BE at 80 mg/kg was administrated through the oral route in J20 AD transgenic mice aged from aged 4 months to aged 10 months. Metabolic- and neurobehavioural phenotyping was done before and after 6 months' treatment to evaluate the drug efficacy and the relevant mechanisms. Meanwhile, molecular docking was used to study the binding affinity of BE and poly (ADP-ribose) polymerase-1 (PARP-1) which is related to neuronal injury. The open field test showed that BE could suppress hyperactivity in J20 mice and increase the frequency of the target quadrant crossing in the Morris Water Maze test. More importantly, BE restored cerebral blood flow back to the normal level after the chronic treatment. A 1 H NMR-based metabolomics study showed that BE treatment could restore the tricarboxylic acid cycle in plasma. And such a treatment could suppress oxidative stress, inhibit neuroinflammation, alleviate mitochondrial dysfunction, improve neurotransmission, and restore amino homeostasis via starch and sucrose metabolism and glycolipid metabolism in the cortex and hippocampus, which could affect the behavioural and cerebral blood flow. These findings showed that BE is a potential therapeutic agent for AD.
Competing Interests: The authors report no competing interest.
(© 2023 The Authors. Published by Elsevier Inc.)
References: Biomaterials. 2013 May;34(15):3870-81. (PMID: 23453061)
Neuron. 2008 Oct 23;60(2):247-57. (PMID: 18957217)
J Pharm Biomed Anal. 2015 Jan;102:425-35. (PMID: 25459942)
Biochim Biophys Acta. 2011 Nov;1812(11):1371-9. (PMID: 21867751)
Behav Brain Res. 2011 Sep 12;222(1):169-75. (PMID: 21443906)
Br J Pharmacol. 2022 May;179(9):1825-1838. (PMID: 33555034)
J Proteome Res. 2016 Feb 5;15(2):608-18. (PMID: 26717242)
J Vis Exp. 2018 Mar 8;(133):. (PMID: 29578495)
Angew Chem Int Ed Engl. 2010 Jul 26;49(32):5426-45. (PMID: 20629054)
Brain Res. 2009 Jan 16;1249:212-21. (PMID: 18977207)
J Pharm Biomed Anal. 2015 Mar 25;107:75-81. (PMID: 25575172)
Electrophoresis. 2015 Feb;36(4):577-87. (PMID: 25393935)
Life Sci. 2017 Mar 15;173:1-10. (PMID: 27693383)
J Pharm Biomed Anal. 2020 Sep 10;189:113424. (PMID: 32619729)
Stroke. 2012 Nov;43(11):3052-62. (PMID: 22923448)
Int J Pharm. 2020 Dec 15;591:120002. (PMID: 33141084)
J Proteomics. 2014 Jun 02;104:37-47. (PMID: 24473279)
J Cereb Blood Flow Metab. 2013 Sep;33(9):1412-21. (PMID: 23801246)
Pharmacol Biochem Behav. 2014 Nov;126:28-35. (PMID: 25242810)
J Vis Exp. 2015 May 04;(99):e52675. (PMID: 25993394)
Hypertension. 2019 Aug;74(2):413-420. (PMID: 31203725)
Mech Ageing Dev. 2015 Mar;146-148:53-64. (PMID: 25881554)
J Alzheimers Dis. 2017;57(4):1071-1086. (PMID: 27662318)
Science. 2016 May 6;352(6286):712-716. (PMID: 27033548)
Brain Behav Immun. 2021 Jul;95:330-343. (PMID: 33839232)
PLoS One. 2015 May 14;10(5):e0126952. (PMID: 25974350)
Biochem Biophys Res Commun. 2019 Apr 2;511(2):454-459. (PMID: 30803762)
Neurochem Int. 2010 Jul;56(8):937-47. (PMID: 20398713)
Int J Pharm. 2020 Aug 30;586:119546. (PMID: 32544519)
Curr Alzheimer Res. 2014;11(9):869-81. (PMID: 25274114)
J Pharm Biomed Anal. 2015 Mar 25;107:378-85. (PMID: 25656489)
Int J Pharm. 2020 Dec 15;591:119981. (PMID: 33069896)
J Pharm Biomed Anal. 2015 Nov 10;115:174-82. (PMID: 26210744)
Electrophoresis. 2013 Oct;34(19):2865-72. (PMID: 23857558)
J Neurol Sci. 2013 Jun 15;329(1-2):29-33. (PMID: 23566485)
Life Sci. 2021 Feb 15;267:118975. (PMID: 33387580)
Curr Drug Targets Cardiovasc Haematol Disord. 2005 Apr;5(2):177-84. (PMID: 15853750)
J Proteome Res. 2014 Oct 3;13(10):4457-69. (PMID: 25164377)
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 15;1126-1127:121739. (PMID: 31430683)
J Chromatogr A. 2013 Aug 9;1302:65-71. (PMID: 23827464)
J Cereb Blood Flow Metab. 2017 Mar;37(3):1120-1136. (PMID: 27339263)
Neurosci Biobehav Rev. 2011 May;35(6):1397-409. (PMID: 21392524)
Biomedicines. 2020 Dec 09;8(12):. (PMID: 33317213)
PLoS One. 2013 May 20;8(5):e63644. (PMID: 23700429)
J Proteomics. 2019 May 30;200:144-152. (PMID: 30978462)
Biochimie. 2015 Mar;110:119-128. (PMID: 25597416)
Neurosci Biobehav Rev. 2017 Jan;72:168-175. (PMID: 27908711)
Front Mol Biosci. 2018 Apr 09;5:28. (PMID: 29686991)
J Alzheimers Dis. 2014;39(1):121-43. (PMID: 24145382)
Cell Mol Life Sci. 2019 Jul;76(14):2739-2760. (PMID: 31016348)
Biochim Biophys Acta. 2014 Aug;1842(8):1232-9. (PMID: 23816564)
Apoptosis. 2020 Jun;25(5-6):354-369. (PMID: 32338336)
J Proteome Res. 2014 May 2;13(5):2649-58. (PMID: 24694177)
J Neurochem. 1986 Apr;46(4):1042-5. (PMID: 3950618)
Life Sci. 2020 Aug 15;255:117861. (PMID: 32473247)
Life Sci. 2021 Oct 1;282:119824. (PMID: 34265361)
Biochim Biophys Acta. 2014 Dec;1842(12 Pt A):2395-402. (PMID: 25281826)
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jul 15;1178:122859. (PMID: 34274605)
فهرسة مساهمة: Keywords: Alzheimer's disease; Baicalein; Cerebral blood flow; Chronic study; Metabolomics; Neurobehavioural test
تواريخ الأحداث: Date Created: 20230223 Latest Revision: 20230224
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9931920
DOI: 10.1016/j.bbih.2023.100599
PMID: 36817510
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-3546
DOI:10.1016/j.bbih.2023.100599